^
    Back
    Association details:
    Biomarker:DNMT3A mutation
    Cancer:T Cell Non-Hodgkin Lymphoma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Blood Adv
    Title:

    Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma

    Published date:
    01/22/2021
    Excerpt:
    Here, we present the results of a phase 2 trial combining lenalidomide and CHOP in previously untreated AITL patients aged 60 to 80 years...patients with mutations in the 3 epigenetic modifiers TET2, DNMT3A, and IDH2 had a poor prognosis, with a median OS of 14 months when treated with CHOP-based therapy.
    Secondary therapy:
    CHOP
    DOI:
    10.1182/bloodadvances.2020003081
    Trial ID:
    NCT01553786